富马酸替诺福韦二吡呋酯致肾损伤的主动监测与危险因素分析

王亚亚; 丁丽; 史国琴; 滕月鹏; 李彩东; 郭文娟; 缪苗苗; 魏秋芳; 古殿杰

doi:10.6039/j.issn.1001-0408.2022.22.17

您当前的位置：

首页 >

文章列表页 >

富马酸替诺福韦二吡呋酯致肾损伤的主动监测与危险因素分析

药物与临床 | 更新时间：2023-02-22

- 富马酸替诺福韦二吡呋酯致肾损伤的主动监测与危险因素分析
- Active monitoring and risk factor analysis of tenofovir disoproxil fumarate-induced kidney injury
- 中国药房 2022年33卷第22期页码：2770-2774
- 作者机构：
  
  1.兰州市第二人民医院药剂科，兰州　730046
  2.兰州市第二人民医院肝病研究所，兰州　730046
- 作者简介：
  
  主管药师，硕士。研究方向：药品不良反应。电话：0931-8373316。E-mail：1328019908@qq.com
  主任药师，硕士。研究方向：临床药学、药事管理。电话：0931-8361836。E-mail：393916208@qq.com
- 基金信息：
  
  甘肃省药品监督管理局科研项目(2022GSMPA0039);兰州市人才创新创业项目(2018-RC-46);兰州市科技计划项目(2022-ZD-16)
- DOI：10.6039/j.issn.1001-0408.2022.22.17
  中图分类号： R978.7;R969.3
- 纸质出版日期：2022-11-30，
  
  收稿日期：2022-05-18，
  
  修回日期：2022-10-22，
扫描看全文
王亚亚,丁丽,史国琴等.富马酸替诺福韦二吡呋酯致肾损伤的主动监测与危险因素分析 ^Δ[J].中国药房,2022,33(22):2770-2774.

WANG Yaya,DING Li,SHI Guoqin,et al.Active monitoring and risk factor analysis of tenofovir disoproxil fumarate-induced kidney injury[J].ZHONGGUO YAOFANG,2022,33(22):2770-2774.
王亚亚,丁丽,史国琴等.富马酸替诺福韦二吡呋酯致肾损伤的主动监测与危险因素分析 ^Δ[J].中国药房,2022,33(22):2770-2774. DOI： 10.6039/j.issn.1001-0408.2022.22.17.

WANG Yaya,DING Li,SHI Guoqin,et al.Active monitoring and risk factor analysis of tenofovir disoproxil fumarate-induced kidney injury[J].ZHONGGUO YAOFANG,2022,33(22):2770-2774. DOI： 10.6039/j.issn.1001-0408.2022.22.17.

摘要

目的

监测富马酸替诺福韦二吡呋酯（TDF）致肾损伤的发生情况并探讨其危险因素，为指导临床安全使用TDF提供参考。

方法

利用中国医院药物警戒系统（CHPS）收集2019年1月1日至2021年12月31日在兰州市第二人民医院使用TDF的乙型肝炎住院患者信息，根据肾损伤标准设置检索条件，对TDF致肾损伤疑似患者进行主动监测，再由临床药师逐一判定后确认TDF致肾损伤阳性患者，计算TDF致肾损伤发生率；分析纳入患者的基本信息、肝肾功能主要检验指标、合并疾病、合用药物情况与TDF致肾损伤的相关性，探索真实世界中TDF致肾损伤的危险因素。

结果

共纳入1 226例使用TDF的乙型肝炎住院患者，经CHPS主动监测发现160例TDF致肾损伤疑似患者，最终人工确认64例阳性患者，TDF致肾损伤发生率为5.22%。与用药前相比，阳性患者用药后血肌酐、胱抑素C水平和尿蛋白2+及以上患者比例均显著升高（

＜0.001），估测肾小球滤过率和血磷水平均显著降低（

＜0.001），其余指标差异无统计学意义。患者用药时间超过36个月、疾病进展为肝硬化失代偿期、合用药物超过10种均与TDF致肾损伤有显著相关性（

＜0.05或

＜0.012 5）。

结论

应用CHPS建立的TDF致肾损伤主动监测方案具有省时、省力、高效的特点；基于当前真实世界证据，当患者使用TDF时，应注意密切监测肾功能情况，尤其当用药时间较长、疾病进展为肝硬化失代偿期以及需要合用多种药物时，更应提高警惕，进而早期发现、有效规避高危患者不良反应风险。

Abstract

OBJECTIVE

To monitor the occurrence of tenofovir disoproxil fumarate （TDF）-induced kidney injury and investigate the risk factors， and provide reference for rational use of TDF in clinic.

METHODS

The information of inpatients with hepatitis B was collected by China Hospital Pharmacovigilance System （CHPS） from the Second People’s Hospital of Lanzhou during Jan. 1st， 2019 to Dec. 31st 2021. The search criteria were set according to kidney injury criteria， and suspected TDF-induced kidney injury cases were actively monitored； then the clinical pharmacist confirmed the positive patients with TDF-induced kidney injury one by one and calculated the incidence of TDF-induced renal injury； the risk factors for TDF-induced kidney injury in real world were explored by collecting and analyzing the correlation of basic data of patients， main indexes of liver and kidney function， complications and combined use of drugs with TDF-induced renal indexes.

RESULTS

Totally 1 226 inpatients with hepatitis B using TDF were included. Through active monitoring of CHPS， 160 suspected patients with TDF-induced kidney injury were found， and 64 positive patients were finally confirmed manually. The incidence of TDF-induced kidney injury was 5.22%. Compared with pre-medication， the levels of serum creatinine and cystatin C， the proportion of patients with urinary protein 2+ and above were increased significantly after medication （

＜0.001）， glomerular filtration rate and blood phosphorus level were reduced significantly （

＜0.001） and other indicators had no statistical difference. Treatment time for more than 36 months， disease progresses to decompensated cirrhosis， and concomitant use of more than 10 kinds of drugs were significantly correlated with TDF-related kidney injury （

＜0.05 or

＜0.012 5）.

CONCLUSIONS

The active monitoring scheme of TDF-induced kidney injury established by CHPS has the characteristics of time-saving， labor-saving and high efficiency； based on real-world evidence， it is imperative to strengthen monitoring kidney function of patients when using TDF， especially when the patient has been on medication for a long time， in decompensated cirrhosis and combination of multiple drugs， and thus， we can identify earlier and avoid adverse effects in high-risk patients effectively.

关键词

富马酸替诺福韦二吡呋酯肾损伤中国医院药物警戒系统主动监测药品不良反应真实世界

Keywords

kidney injuryChina Hospital Pharmacovigilance Systemactive monitoringadverse drug reactionreal world

references

中华医学会感染病学分会，中华医学会肝病学分会. 慢性乙型肝炎防治指南：2019年版[J]. 中华肝脏病杂志，2019，27（12）：938-961.

冯淑焕，唐克诚，李谦. 替诺福韦酯治疗多重耐药慢性乙型肝炎的回顾性分析[J]. 中国药房，2015，26（23）：3251-3252.

LIANG X E，GAO Z L，XIE Q，et al. Long-term efficacy and safety of tenofovir disoproxil fumarate in Chinese patients with chronic hepatitis B：5-year results[J]. Hepatol Int，2019，13（3）：260-269.

DE FRAGA R S，VAN VAISBERG V，MENDES L C A，et al. Adverse events of nucleos（t）ide analogues for chronic hepatitis B：a systematic review[J]. J Gastroenterol，2020，55（5）：496-514.

U.S. Department of health and human services， National Institutes of Health National Cancer Institute. Common Terminology Criteria for Adverse Events（CTCAE）Version 5.0[EB/OL].（2017-11-27）[2022-04-23]. http：//ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htmhttp://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm.

赖玮婧，刘芳，付平. 慢性肾脏病评估及管理临床实践指南解读：从K/DOQI到KDIGO[J]. 中国实用内科杂志，2013，33（6）：448-453.

LEVEY A S，STEVENS L A，SCHMID C H，et al. A new equation to estimate glomerular filtration rate[J]. Ann Intern Med， 2009，150（9）：604-612.

LIU J，LIANG W，JING W，et al. Countdown to 2030：eliminating hepatitis B disease，China[J]. Bull World Health Organ，2019，97（3）：230-238．

缪苗苗，万志娜，丁丽，等. 甘肃省居民乙肝防治知识态度行为调查分析[J]. 当代医学，2020，26（1）：15-17.

KOKLU S，GULSEN M T，TUNA Y，et al. Differences in nephrotoxicity risk and renal effects among anti-viral therapies against hepatitis B[J]. Aliment Pharmacol Ther，2015，41（3）：310-319.

抗乙型肝炎病毒核苷（酸）类似物不良反应管理专家委员会. 抗乙型肝炎病毒核苷（酸）类似物不良反应管理专家共识[J/OL]. 中国肝脏病杂志（电子版），2016，8（3）：10-14. http：//zggzbzz.j-ditan.com/Magazine/PDFShow.aspx?ID=138922http://zggzbzz.j-ditan.com/Magazine/PDFShow.aspx?ID=138922.

LEOWATTANA W. Antiviral drugs and acute kidney injury（AKI）[J]. Infect Disord Drug Targets，2019，19（4）：375-382.

MAK L Y，SETO W K，LAI C L，et al. DNA polymerase inhibitors for treating hepatitis B：a safety evaluation[J]. Expert Opin Drug Saf，2016，15（3）：383-392.

PIPILI C，CHOLONGITAS E，PAPATHEODORIDIS G. Review article：nucleos（t）ide analogues in patients with chronic hepatitis B virus infection and chronic kidney disease[J]. Aliment Pharmacol Ther，2014，39（1）：35-46.

CHENG C Y，CHANG S Y，LIN M H，et al. Tenofovir disoproxil fumarate-associated hypophosphatemia as determined by fractional excretion of filtered phosphate in HIV-infected patients[J]. J Infect Chemother，2016，22（11）：744-747.

HAVENS P L，KISER J J，STEPHENSEN C B，et al. Association of higher plasma vitamin D binding protein and lower free calcitriol levels with tenofovir disoproxil fumarate use and plasma and intracellular tenofovir pharmacokinetics：cause of a functional vitamin D deficiency? [J]. Antimicrob Agents Chemother，2013，57（11）：5619-5628.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

伏立康唑原研药与仿制药的有效性、安全性及经济性评价

聚异丁烯型骨通贴膏用于中国成人骨关节炎的有效性、安全性和经济性

基于真实世界的3种止吐方案预防含顺铂多日化疗相关恶心呕吐的成本-效用分析